Tetra Bio-Pharma announced that the company’s investigational new drug involving cannabinoids, QIXLEEF, received guidance to strengthen its nonclinical and toxicological data from the U.S. Food and Drug Administration, which brings the aerosol botanical therapy closer to marketing approval.

Rivus Pharmaceuticals, a biopharma company focused on therapies for cardiometabolic health, announced positive data from a Phase IIa clinical trial.

New York-based Ovid Therapeutics and Healx entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).

A new study by the American Stroke Association found that the risk of stroke in adults with COVID-19 between the ages of 65 to 74 was highest the first three days after diagnosis. Additionally, investigators at the National Institutes of Allergy and Infectious Diseases’ Vaccine Research Center ran tests on primates and found that updating COVID-19 vaccines to focus on the Omicron variant may not provide much benefit.

Less than a month after submitting an Investigational New Drug (IND) application, Anixa Biosciences ran into a snag with the U.S. Food and Drug Administration as the government agency asked for more information before approving a clinical study on the company’s Chimeric Antigen Receptor-T cell therapy (CAR-T).

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

Vancouver, Washington-based CytoDyn filed a second clinical trial protocol with the U.S. Food and Drug Administration to treat severely sick COVID-19 patients.

In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though. What may be more effective in the long run, is hitting a disease along multiple target lines. That is the idea at Cambridge, Mass.-based Immuneering.

The U.S. FDA placed a hold on Seattle Genetics’ Investigational New Drug Application for vadastuximab talirine.

Shares of Arrowhead Pharmaceuticals were down after the company’s experimental hepatitis B drug, ARC-520, was placed on clinical hold by the U.S. FDA.